Forecast
The analysts' average price target is âŹ99.79 (+39,816.00%). The median is âŹ99.79 (+39,816.00%).
| Buy |
Â
5 |
| Hold |
Â
5 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last year, ALLAKOS INC. DL-,001 Aktie had revenue of âŹ0 and net profit of -âŹ111.3M
| (EUR) | 2024 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -7.42M | 33.62% |
| Net profit | -111.3M | 33.74% |
| EBITDA | -103.88M | 39.53% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ27.11M |
Number of shares | 90.38M |
52-week high/low | âŹ1.42 - âŹ0.20 |
| Dividends | No |
Beta | 0.14 |
P/E ratio | -0.25 |
PEG ratio | 0.00 |
P/B ratio | 0.37 |
P/S ratio | 0.00 |
Company profile
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
| Name | ALLAKOS INC. DL-,001 Aktie |
| CEO | Robert Alexander |
| Headquarters | San Carlos,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 07/19/2018 |
| Employees | 131 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ALLK |
Frankfurt | 37Z.F |
DĂŒsseldorf | 37Z.DU |
MĂŒnchen | 37Z.MU |